A carregar...
Acquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon EGFR mutations: a case report and literature review
BACKGROUND: Osimertinib is the standard of care for patients with non-small-cell lung cancer (NSCLC) patients harboring acquired EGFR T790M resistance mutation. However, the frequency of T790M resistance mutation acquisition and the efficacy of osimertinib in patients harboring uncommon EGFR mutatio...
Na minha lista:
| Publicado no: | Onco Targets Ther |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6348971/ https://ncbi.nlm.nih.gov/pubmed/30774361 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S190034 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|